DOCSLIB.ORG

Tarif Intégré Des Communautés Européennes (TARIC)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tarif Intégré Des Communautés Européennes (TARIC) 1 . 4. 96 FR Journal officiel des Communautés européennes 3101 I (Communications) COMMISSION Tarif intégré des Communautés européennes (TARIC) Volume IV — Annexes (96/C 98 A/01 ) TABLE DES MATIERES Page Annexe 1 : Codes additionnels pour les elements agricoles , codes additionnels et droits additionnels sur le sucre et sur la farine et prix de référence du poisson . 3103 Annexe 2: Listes des substances pharmaceutiques 3169 Annexe 3 : CITES 3277 1 . 4. 96 | FR I Journal officiel des Communautés européennes 3103 ANNEXE 1 — CODES ADDITIONNELS POUR LES ELEMENTS AGRICOLES — CODES ADDITIONNELS ET DROITS ADDITIONNELS SUR LE SUCRE ET LA FARINE — PRIX DE REFERENCE DU POISSON 3104 I FR Journal officiel des Communautés européennes 1 . 4 . 96 CODES ADDITIONNELS POUR TABLEAU DES CHAPI Code de composition (code additionnel) de certaines >0 <5 Proteines du lait Code NC Matieres grasses du lait (% en poids) (% en poids) r >0 >5 > 30 > 50 > 70 <5 < 30 < 50 < 70 0405 20 10 1905 30 11 > 0<1,5 > 0 < 2,5 7000 7001 7002 7003 7004 0405 20 30 1905 30 19 > 2,5 <6 7020 7021 7022 7023 7024 1905 30 30 > 6 < 18 7040 7041 7042 7043 7044 1704 90 51 1905 30 51 > 18 < 30 7060 7061 7062 7063 7064 1704 90 55 1905 30 59 > 30 < 60 7080 7081 7082 7083 7084 1704 90 61 1905 30 91 > 60 7800 7801 7802 x x 1704 90 65 1905 30 99 1704 90 71 1905 40 10 > 1,5<3 > 0 < 2,5 7100 7101 7102 7103 7104 1704 90 75 1905 40 90 > 2,5 <6 7120 7121 7122 7123 7124 1704 90 81 1905 90 30 > 6 < 18 7140 7141 7142 7143 7144 1704 90 99 1905 90 40 > 18 < 30 7160 7161 7162 7163 7164 1905 90 45 > 30 < 60 7180 7181 7182 7183 x 10 1905 90 55 1806 20 > 60 7820 7821 7822 x x 1806 20 30 1905 90 60 1806 20 50 1905 90 90 > 3<6 7840 7841 7842 7843 7844 1806 20 70 > 0 < 2,5 7200 7201 7202 7203 7204 1806 20 80 2004 10 91 > 2,5 < 1 2 > 12 7260 7261 7262 7263 7264 1806 20 95 2005 20 10 1806 31 00 1806 32 10 2101 12 98 > 6<9 >0 <4 7860 7861 7862 7863 7864 1806 32 90 2101 20 98 >4 < 1 5 7300 7301 7302 7303 7304 1806 90 11 2106 10 80 > 15 7360 7361 7362 7363 7364 1806 90 19 2106 90 98 1806 90 31 > 9 < 1 2 > 0<6 7900 7901 7902 7903 7904 1806 90 39 > 6 < 18 7400 7401 7402 7403 7404 1806 90 50 > 18 7460 7461 7462 7463 7464 1806 90 60 1806 90 70 > 1 2 < 1 8 >0 < 6 7940 7941 7942 7943 7944 1806 90 90 > 6 < 1 8 7500 7501 7502 7503 7504 > 18 7560 7561 7562 7563 7564 1901 10 00 1901 20 00 1901 90 99 > 1 8 < 26 > 0<6 7960 7961 7962 7963 7964 >6 7600 7601 7602 7603 7604 1904 20 10 > 26 < 40 > 0<6 7980 7981 7982 7983 7984 >6 7700 7701 7702 7703 x > 40 < 55 7720 7721 7722 7723 x > 55 < 70 7740 7741 7742 x x > 70<8 5 7760 7761 7762 x x > 85 7780 7781 x x x (') Les caséines et/ou les caséinates entrant dans la composition de la marchandise ne sont pas retenus comme proteines du lait si la marchandise ne contient pas d'autres composants d'origine lactique . Les matières grasses du lait contenues dans les marchandises à des teneurs inférieures à 1 % et le lactose à des teneurs inférieures à 1 % en poids ne sont pas considérés comme autres composants d'origine lactique . Lors de l'accomplissement des formalités douanières, l'intéressé est tenu d'indiquer dans la déclaration prévue à cet effet : « seul ingrédient lactique : caséine/caséinate », si tel est le cas. ( 2) La teneur de la marchandise (en l'état) en amidon ou fécule , leurs produits de dégradation (tous les polymères du glucose compris), et le glucose éven­ tuellement présent, déterminés sur la base de glucose et exprimés en amidon (substance sèche , pureté 100 % ; facteur de conversion du glucose en amidon : 0,9). Toutefois le glucose est repris dans le calcul ci-dessus seulement dans son pourcentage qui excède la quantité de fructose, si un mélange de glucose et de fructose est déclaré (sous quelque forme que ce soit) et/ou trouvé présent dans la marchandise . (') La teneur de la marchandise (en l'état) en saccharose, additionnée du saccharose qui résulte du calcul en saccharose de tout mélange de glucose et de fructose (somme arithmétique des quantités de deux sucres multipliée par 0,95), qui sera déclaré (sous quelque forme que ce soit) et/ou trouvé présent dans la marchandise . Toutefois, si le contenu en fructose est inférieur à celui du glucose dans le calcul précédent, on ne tiendra compte du glucose que jusqu'à un contenu égal à celui du fructose . NB: Dans tous les cas et lorsque la présence d'un hydrolysat de lactose est déclarée et/ou une quantité de galactose est déterminée parmi les sucres, la quantité de glucose équivalente au galactose est déduite de la quantité totale de glucose avant que tout autre calcul soit effectué . 1 . 4 . 96 FR Journal officiel des Communautés européennes 3105 LES ÉLÉMENTS AGRICOLES TRES 14-17-18-19-20-21 marchandises relevant du règlement (CE) n° 3448/93 Amidon-fécule / Glucose (% en poids) (2) >5 < 25 > 25 < 50 > 50 < 75 > 75 Saccharose / Sucre inverti / Isoglucose (% en poids) (r >0 >5 > 2,030 > 50 >0 >5 > 30 >0 >5 >0 > 70 > 50 > 30 >5 <5 < 30 < 50 < 70 <5 < 30 < 50 <5 < 30 <5 7005 7006 7007 7008 7009 7010 7011 7012 7013 7015 7016 7017 7758 7759 7025 7026 7027 7028 7029 7030 7031 7032 7033 7035 7036 7037 7768 7769 7045 7046 7047 7048 7049 7050 7051 7052 7053 7055 7056 7057 7778 7779 7065 7066 7067 7068 7069 7070 7071 7072 7073 7075 7076 7077 7788 7789 7085 7086 7087 7088 x 7090 7091 7092 x 7095 7096 x x x 7805 7806 7807 x x 7810 7811 x x x x x x x 7105 7106 7107 7108 7109 7110 7111 7112 7113 7115 7116 7117 7798 7799 7125 7126 7127 7128 7129 7130 7131 7132 7133 7135 7136 7137 7808 7809 7145 7146 7147 7148 7149 7150 7151 7152 7153 7155 7156 7157 7818 7819 7165 7166 7167 7168 7169 7170 7171 7172 7173 7175 7176 7177 7828 7829 7185 7186 7187 7188 x 7190 7191 7192 x 7195 7196 x x x 7825 7826 7827 x x 7830 7831 x x x x x x x 7845 7846 7847 7848 7849 7850 7851 7852 7853 7855 7856 7857 7858 7859 7205 7206 7207 7208 7209 7210 7211 7212 7213 7215 7216 7217 7220 7221 7265 7266 7267 7268 7269 7270 7271 7272 7273 7275 7276 x 7838 x 7865 7866 7867 7868 7869 7870 7871 7872 7873 7875 7876 7877 7878 7879 7305 7306 7307 7308 7309 7310 7311 7312 7313 7315 7316 7317 7320 7321 7365 7366 7367 7368 7369 7370 7371 7372 7373 7375 7376 x 7378 x 7905 7906 7907 7908 7909 7910 7911 7912 7913 7915 7916 7917 7918 7919 7405 7406 7407 7408 7409 7410 7411 7412 7413 7415 7416 7417 7420 7421 7465 7466 7467 7468 x 7470 7471 7472 x 7475 7476 x x x 7945 7946 7947 7948 7949 7950 7951 7952 7953 7955 7956 7957 7958 7959 7505 7506 7507 7508 7509 7510 7511 7512 7513 7515 7516 7517 7520 7521 7565 7566 7567 7568 x 7570 7571 7572 x 7575 7576 x x x 7965 7966 7967 7968 7969 7970 7971 7972 7973 7975 7976 7977 7978 7979 7605 7606 7607 7608 7609 7610 7611 7612 7613 7615 7616 x 7620 x 7985 7986 7987 7988 x 7990 7991 7992 x 7995 7996 x x x 7705 7706 7707 7708 x 7710 7711 7712 x 7715 7716 x x x 7725 7726 7727 7728 x 7730 7731 7732 x 7735 7736 x x x 7745 7746 7747 x x 7750 7751 x x x x x x x 7765 7766 x x x 7770 7771 x x x x x x x 7785 7786 x x x x x x x x x x x x 3106 FR Journal officiel des Communautés européennes 1 . 4 . 96 CODES ADDITIONNELS ET DROITS ADDITIONNELS SUR LE SUCRE ET LA FARINE ERGA OMNES-CEE EA AD S/Z AD F/M EA AD S/Z AD F/M Code Code additionnel additionnel Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net 7000 0 0 0 7060 107.67 0 0 7001 12.16 12.16 0 7061 119.82 12.16 0 7002 22.8 22.8 0 7062 130.46 22.8 0 7003 32.93 32.93 0 7063 130.63 32.93 0 7004 47.12 47.12 0 7064 151.8 47.12 0 7005 6.11 0 6.11 7065 113.77 0 6.11 7006 18.27 12.16 6.11 7066 125.93 12.16 6.11 7007 28.9 22.8 6.11 7067 136.56 22.8 6.11 7008 39.03 32.93 6.11 7068 143.72 32.93 6.11 7009 53.22 47.12 6.11 7069 157.91 47.12 6.11 7010 13.05 0 13.05 7070 120.71 0 13.05 7011 25.21 12.16 13.05 7071 132.88 12.16 13.05 7012 35.84 22.8 13.05 7072 143.5 22.8 13.05 7013 45.98 32.93 13.05 7073 1 50.68 32.93 13.05 7015 20.54 0 20.54 7075 125.24 0 20.54 7016 32.7 12.16 20.54 7076 137.4 12.16 20.54 7017 43.34 22.8 20.54 7077 148.02 22.8 20.54 7020 20.1 0 0 7080 209.58 0 0 7021 32.26 12.16 0 7081 221.74 12.16 0 7022 42.89 22.8 0 7082 232.39 22.8 0 7023 52.48 32.93 0 7083 236.73 32.93 0 7024 66.66 47.12 0 7084 250.91 47.12 0 7025 26.21 0 6.11 7085 215.69 0 6.11 7026 38.37 12.16 6.11 7086 227.84 12.16 6.11 7027 49 22.8 6.11 7087 238.48 22.8 6.11 7028 58.58 32.93 6.11 7088 242.84 32.93 6.11 7029 72.77 47.12 6.11 7090 222.62 0 13.05 7030 33.14 0 13.05 7091 234.81 12.16 13.05 7031 45.3 12.16 13.05 7092 245.43 22.8 13.05 7032 55.94 22.8 13.05 7095 224.34 0 20.54 7033 65.52 32.93 13.05 7096 236.51 12.16 20.54 7035 40.08 0 20.54 7100 8.36 0 0 7036 52.24 12.16 20.54 7101 20.51 12.16 0 7037 62.89 22.8 20.54 7102 31.15 22.8 0 7040 60.29 0 0 7103 41.28 32.93 0 7041 72.45 12.16 0 7104 55.47 47.12 0 7042 83.08 22.8 0 7105 14.46 0 6.11 7043 91.56 32.93 0 7106 26.62 12.16 6.11 7044 105.74 47.12 0 7107 37.26 22.8 6.11 7045 66.4 0 6.11 7108 47.39 32.93 6.11 7046 78.56 12.16 6.11 7109 61.57 47.12 6.11 7047 89.19 22.8 6.11 7110 21.4 0 13.05 7048 97.66 32.93 6.11 7111 33.55 12.16 13.05 7049 111.85 47.12 6.11 7112 44.2 22.8 13.05 7050 73.34 0 13.05 7113 54.33 32.93 13.05 7051 85.5 12.16 13.05 7115 28.9 0 20.54 7052 96.13 22.8 13.05 7116 41.06 12.16 20.54 7053 104.6 32.93 13.05 7117 51.69 22.8 20.54 7055 79.17 0 20.54 7120 28.45 0 0 7056 91.34 12.16 20.54 7121 40.61 12.16 0 7057 101.97 22.8 20.54 7122 51.25 22.8 0 1 .
Load more

Recommended publications
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • TARIF DES DOUANES - ANNEXE 99 - I
    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Drug Antioxidant Effects a Basis for Drug Selection?
    REVIEW ARTI LE Drugs 42 (4): 569-605, 1991 00 12-6667/ 91/ 00 I0-0569/ $ 18.50/0 © Adis International Limited. All rights reserved. DRU161 Drug Antioxidant Effects A Basis for Drug Selection? Barry Halliwell Pulmonary Medicine, UC Davis Medical Center, Sacramento , California, USA Contents 570 Summary 570 I. What is a Free Radical? 570 1.1 Definition of a Free Radical 57/ 1.2 Hydroxyl Radical 572 1.3 Formation of Oxygen Radicals In Vivo 574 1.4 Reactive Oxygen Species 575 1.5 Transition Metal Ions and Free Radical Reactions 575 1.6 Antioxidant Defence In Vivo: Intracellular 576 1.7 Antioxidant Defence In Vivo: Extracellular 579 2. Free Radical Damage to Cells and the Protective Ability of Antioxidants 579 2.1 Mechanisms of Cell Damage: The Molecular Targets 58/ 2.2 How to Characterise an Antioxidant 5 2 3. The Role of Free Radicals in Human Disease 582 3.1 Causation of Disease 582 3.2 A Significant Consequence of Disease Pathology 584 3.3 A General Consequence of Tissue Injury 585 3.4 What Can We Expect from Antioxidant Therapy? 586 586 4. Antioxidants in Disease Therapy 586 4.1 Use of Naturally Occurring Antioxidants and Derived Compounds 587 4.1.1 Superoxide Dismutase 587 4.1.2 Superoxide Dismutase 'Mimics' 588 4.1.3 a-Tocopherol 589 4.1.4 Ascorbic Acid (Vitamin C) 589 4.1.5 Adenosine 589 4.1.6 Lactoferrin 590 4.1.7 Nicotinamide 59/ 4.1.8 Glutathione and its Precursors 59/ 4.1.9 Carotenoids 59/ 4.2 'Synthetic' Antioxidants 59/ 4.2.1 Mercaptopropionylglycine and Other Thiols 592 4.2.2 Ebselen: A Glutathione Peroxidase Mimic? 593 4.2.3 Allopurinol, Oxypurinol and Other Xanth ine Oxidase Inhibitors 593 4.2.4 Inhibitors of the Generation of Reactive Oxygen Species by Phagocytes 595 4.2.5 Chelating Agents: Deferoxamine 595 4.2.6 Other Iron Chelators: Hydroxypyridones 596 4.2.7 Other Iron Chelators: ICRF-187 and the 'Lazaroids' 4.2.8 Probucol and Other Chain-Breaking Antioxidants 570 Drugs 42 (4) 1991 596 5.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Review Article
    Free Radical Biology & Medicine, Vol. 33, No. 6, pp. 774–797, 2002 Copyright © 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0891-5849/02/$–see front matter PII S0891-5849(02)00956-5 Review Article STRUCTURE AND FUNCTION OF XANTHINE OXIDOREDUCTASE: WHERE ARE WE NOW? ROGER HARRISON Department of Biology and Biochemistry, University of Bath, Bath, UK (Received 11 February 2002; Accepted 16 May 2002) Abstract—Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme, present in milk and many other tissues, which has been studied for over 100 years. While it is generally recognized as a key enzyme in purine catabolism, its structural complexity and specialized tissue distribution suggest other functions that have never been fully identified. The publication, just over 20 years ago, of a hypothesis implicating XOR in ischemia-reperfusion injury focused research attention on the enzyme and its ability to generate reactive oxygen species (ROS). Since that time a great deal more information has been obtained concerning the tissue distribution, structure, and enzymology of XOR, particularly the human enzyme. XOR is subject to both pre- and post-translational control by a range of mechanisms in response to hormones, cytokines, and oxygen tension. Of special interest has been the finding that XOR can catalyze the reduction of nitrates and nitrites to nitric oxide (NO), acting as a source of both NO and peroxynitrite. The concept of a widely distributed and highly regulated enzyme capable of generating both ROS and NO is intriguing in both physiological and pathological contexts. The details of these recent findings, their pathophysiological implications, and the requirements for future research are addressed in this review.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski Et Al
    US009687458B2 (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski et al. (45) Date of Patent: Jun. 27, 2017 (54) TRANS-CLOMIPHENE FOR USE IN 6,143,353 A 1 1/2000 Oshlack CANCER THERAPY 6,190,591 B1 2/2001 Van Lengerich 6,221,399 B1 4/2001 Rolfes 6,248,363 B1 6, 2001 Patel (71) Applicant: REPROS THERAPEUTICS INC., 6,291,505 B1 9/2001 Huebner et al. The Woodlands, TX (US) 6,342,250 B1 1/2002 Masters 6,391920 B1 5, 2002 Fisch (72) Inventors: Joseph S. Podolski. The Woodlands, 6,511.986 B2 1/2003 Zhang et al. TX (US); Ronald D. Wiehle, Houston, 826 R $398 Ma'al TX (US); Kuang Hsu, The Woodlands, 6,638,528s- ww. B1 10/2003 KaniosaO ( a. TX (US); Greg Fontenot, The 6,645,974 B2 11/2003 Hutchinson et al. Woodlands, TX (US) 6,653,297 B1 11/2003 Hodgen 6,685,957 B1 2/2004 Bezemer et al. (73) Assignee: Repros Therapeutics Inc., The $33. R: 3. ErSC Woodlands, TX (US) 7,105,679 B2 9/2006 Kanojia et al. 7,354,581 B2 4/2008 Cedarb tal. (*) Notice: Subject to any disclaimer, the term of this 7,799,782 B2 9/2010 T al patent is extended or adjusted under 35 8,247456 B2 8/2012 Podolski U.S.C. 154(b) by 0 days. 8,377,991 B2 2/2013 Van AS 2002/O1200 12 A1 8, 2002 Fisch (21) Appl. No.: 14/440,007 (Continued) (22) PCT Filed: Oct.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]